DAFTAR PUSTAKA

1. James WD, Elston DM, Treat JR, Rosenbach MA, Neuhaus IM. Seborrheic dermatitis, psoriasis, recalcitrant palmoplantar eruptions, pustular dermatitis, and erythroderma. In: Odom RB, James WD, Berger TG, editors. Andrews' Disease of the Skin. 13th ed. Philadelphia: Elsevier; 2020. p. 192.

2. Segar D, Praharsini I, Indira IE. Prevalence and clinical manifestations of patients with psoriasis in RSUP Sanglah from 2017 to 2018. Intisari Sains Medis. 2019;10(3):840–5.

3. Gudjonsson JE, Elder JT. Psoriasiform disorders. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editors. Fitzpatick's Dermatology. 9th ed. New York: McGraw-Hill Education; 2019. p. 457–518.

4. Jacoeb TNA. Psoriasis. In: Menaldi SLS, Bramono K, Indritami W, editors. Ilmu penyakit kulit dan kelamin. 7th ed. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2016. p. 211–21.

5. Prakoeswa CRS, Hidayati AN, Hendaria MP, Listiawan MY, Utomo B, Damayanti, et al. The profile of psoriasis vulgaris patients: a descriptive study. Berkala Ilmu Kesehatan Kulit dan Kelamin. 2021;33(3):173–82.

6. Rahmayunita G, Pulungan AB, Wiryadi BE, Wardhani Wisesa T, Lestari Sugito T, Aisah Boediardja S. Cushing's syndrome induced by misuse of topical corticosteroids in a child with psoriasis vulgaris. Cushing's syndrome from topical corticosteroids. 17(4):281–6.

7. Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):1–14.

8. Brazzelli V, Maffioli P, Bolcato V, Ciolfi C, D'Angelo A, Tinelli C, et al. Psoriasis and diabetes, a dangerous association: Evaluation of insulin resistance, lipid abnormalities, and cardiovascular Risk Biomarkers. Front Med (Lausanne). 2021;8.

9. da Silva MFP, Fortes MRP, Miot LDB, Marques SA. Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. An Bras Dermatol. 2019;88(5):760–3.

10. Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M. Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish register patients. Am J Clin Dermatol. 2017;18(4):583–90.

11. Wahyudi DT, Novianto E, Fitri EM, Rahmayunita G, Budianti WK. Alur Tata Laksana Psoriasis di Indonesia. 1st ed. Wahyudi DT, Novianto E, Fitri

EM, Rahmayunita G, Budianti WK, editors. Jakarta: UI Publishing; 2024. 1–5 p.

12. Liluashvili S, Kituashvili T. Dermatology life quality index and disease coping strategies in psoriasis patients. Advances in Dermatology and Allergology. 2019;36(4):419–24.

13. Chen Y, Wei L, Song Y, Zhang R, Kuai L, Li B, et al. Life quality among psoriasis patients based on dermatology life quality index evaluation and its association with psoriasis severity in china: a cross-sectional study. Ann Med. 2023;55(1).

14. Oguz Topal I, Kara Polat A, Zindancı İ, Kıvanç Altunay İ, Akbulut TÖ, Arıkan EE, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2022;21(1):39–47.

15. Thamtono Y. Hubungan psoriasis dengan komorbiditas kardiovaskuler. Cermin Dunia Kedokteran-237. 2016;43(2):112–6.

16. Nitiyoso N. Pilihan pengobatan sistemik pada psoriasis. Cermin Dunia Kedokteran-302. 2022;49(3):164–9.

17. Mirghani H, Altemani A, Alsaedi E, Aldawish R, Alharbi M, Alzahrani R, et al. The association of psoriasis, diabetes mellitus, and hypertension: a meta-analysis. Cureus. 2023;15(11).

18. Mala P, Bhattacharjee I, Bhattacharya GC, Ghosh S, Sarker G, Pal R. Association between psoriasis, diabetes mellitus, hypertension and obesity. Clin Epidemiol Glob Health. 2015;3(3):132–6.

19. Kampe T, Dorko E, Rimárová K, Houžvičková A, Baloghová J, Baranová Z, et al. Prevalence of cardiovascular risk factors in patient with psoriasis. Cent Eur J Public Health. 2022;30:S5–10.

20. Brandão GVC, Pereira EG, Haddad GR, Miot LDB, Marques SA, Miot HA. Clinical characterization, physical frailty, and depression in elderly patients with psoriasis from a reference center in Brazil: a cross-sectional study. An Bras Dermatol. 2024;99(1):19–26.

21. Michalek IM, Loring B, John SM, World Health Organization. Global report on psoriasis. 2016.

22. Imafuku S, Zheng M, Tada Y, Zhang X, Theng C, Thevarajah S, et al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. Journal of Dermatology. 2018;45(7):805–11.

23. Alverina L, Hidajat D, Hendrawan IW, Medikawati IGAAR. Karakteristik penderita psoriasis di poliklinik rawat jalan dermatologi dan venereologi

Rumah Sakit Umum Daerah Provinsi Nusa Tenggara Barat periode Januari 2016 – Desember 2020. Intisari Sains Medis. 2021;12(3):880–5.

24. Hanani NK, Ervianti E, Rahniayu A. Clinical profile of psoriasis vulgaris at Soetomo General Hospital, Surabaya. Health Notions. 2020;4(8):282–9.

25. Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci. 2020;99(1):2–8.

26. Dharmawan N, Widhiati S, Oktavriana T, Harahap I. The differences of blood type in relation to psoriasis and its onset: cross sectional study. Journal of General - Procedural Dermatology & Venereology Indonesia. 2021;5(3):142–6.

27. Bhagwat AP, Madke B. The current advancement in psoriasis. Cureus. 2023;15(10).

28. Branisteanu D, Cojocaru C, Diaconu R, Porumb E, Alexa A, Nicolescu A, et al. Update on the etiopathogenesis of psoriasis (Review). Exp Ther Med. 2022;23(3).

29. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6).

30. Koca TT. A short summary of clinical types of psoriasis. North Clin Istanb. 2016;3(1):79–82.

31. D'Ambra I, Babino G, Fulgione E, Calabrese G, Ronchi A, Alfano R, et al. Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: Clinical and dermoscopic patterns. Dermatol Ther. 2020;33(6):1–3.

32. Alajlan AM, Qadoumi TA. Palmoplantar psoriasis successfully treated with risankizumab. Cureus. 2021;13(8).

33. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. Longo DL, editor. New England Journal of Medicine. 2017;376(10):957–70.

34. Yefta M, Retno Adi Winarni D, Widodo Wirohadidjojo Y. Manajemen psoriasis pustulosa. Cermin Dunia Kedokteran-314. 2023;50(3):151–6.

35. Siswati AS, Rosita C, Triwahyudi D, Budianti WK, Mawardi P, Dwiyana RF, et al. Panduan praktik klinis bagi dokter spesialis dermatologi dan venereologi indonesia. Jakarta; 2021.

36. Negrutiu M, Danescu S, Popa T, Focsan M, Vesa SC, Szasz F, et al. Imaging approach in the diagnostics and evaluation of the psoriasis plaque: A preliminary study and literature review. Diagnostics. 2024;14(10).

37. Wu Y, Sun L. Clinical value of dermoscopy in psoriasis. J Cosmet Dermatol. 2024;23(2):370–81.

38. Gharaei Nejad K, Eftekhari H, Rafiei R, Darjani A, Alizadeh N, Ghadarjani R, et al. Matching between ctlinical examination and dermoscopy in patients with nail psoriasis: Should dermoscopy be used instead of clinical examination? Heliyon. 2024;10(8).

39. Kaliyadan F. The dermoscopic auspitz sign. Indian Dermatol Online J. 2018;9(4):290.

40. Decroli E. Dasar-dasar terjadinya DM tipe 2. In: Kam A, Efendi YP, Decroli GP, Rahmadi A, editors. Diabetes Melitus Tipe 2. 1st ed. Padang: Fakultas Kedokteran Universitas Andalas; 2019. p. 4–8.

41. Chiu HY, Hung CJ, Muo CH, Muo CH, Fan KC, Sung FC, et al. The bidirectional association between type 2 diabetes and psoriasis: Two retrospective cohort studies. Indian J Dermatol Venereol Leprol. 2020;86(4):366–74.

42. Tridjaya B, Yati NiP, Faizi M, Marzuki ANS, Moelyo AG, Soesanti F. Diabetes melitus tipe-1. In: Konsesus nasional pengelolaan diabetes melitus tipe-1. 3rd ed. UKK Endokrinologi Anak dan Remaja; 2015.

43. Suprayitna M, Hajri Z, Fatmawati BR, Prihatin K, Nadrati B. Deteksi dini diabetes mellitus (DM) melalui "Mawas DM." BERNAS: Jurnal Pengabdian Kepada Masyarakat. 2023;4(3):2291–6.

44. Resti HY, Cahyati WH. Kejadian diabetes melitus pada usia produktif di puskesmas kecamatan pasar rebo abstrak. Higeia Journal of Public Health Research and Development. 2022;6(3):350–61.

45. Trihono, Thaha AR, Junadi P, Kusnanto H, Sugihantono A, Siswanto, et al. Survei kesehatan indonesia. 2023.

46. Akil AAS, Yassin E, Al-Maraghi A, Aliyev E, Al-Malki K, Fakhro KA. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. J Transl Med. 2021;19(1).

47. Eringsmark Regnéll S, Lernmark Å. The environment and the origins of islet autoimmunity and type 1 diabetes. Diabetic Medicine. 2013;30(2):155–60.

48. Soelistijo SA, Suastika K, Lindarto D, Decroli E, Permana H, Sucipto KW, et al. Pengelolaan diabetes melitus tipe 2. In: Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia. 1st ed. PB Perkeni; 2021. p. 11–3.

49. Susanto SE, Wibowo TH. Effectiveness of giving deep relaxation to reduce pain in hypertension patients in edelweis room down. Jurnal Inovasi Penelitian. 2022;3(4):5841–6.

50. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018.

51. Soenarta AA, Erwinanto, Mumpuni ASS, Barack R, Lukito AA, Hersunarti N, et al. Defenisi dan klasifikasi hipertensi. In: Pedoman Tatalaksana Hipertensi pada Pasien Kardiovaskular. 1st ed. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia; 2015.

52. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37.

53. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primers. 2018;4.

54. Colbert GB, Verner Venegas-Vera A, Lerma E V. Utility of telemedicine in the COVID-19 era. Rev Cardiovasc Med. 2020;21(4):583–7.

55. Lukito AA, Harmeiwaty E, Situmorang TD, Hustrini NM, Kuncoro AS, Barack R, et al. Konsensus Penatalaksanaan Hipertensi. In: Konsensus PERHI. Jakarta; 2021.

56. Surya Rahman Djohar M, Ratio Setiyarso B, Author C. A study of association of psoriasis and type 2 diabetes mellitus: A comprehensive systematic review. Jurnal Sehat Indonesia. 2024;6(2).

57. Kim HN, Han K, Song SW, Lee JH. Hypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study. PLoS One. 2018;13(8).

58. Alajroush WA, Alrshid AI, Alajlan AH, Alsalamah YB, Alhumaidan MI, Alhoumedan AI, et al. Psoriasis and metabolic disorders: A comprehensive meta-analysis of million adults worldwide. Cureus. 2024;16(1):e52099.

59. Cho SI, Kim YE, Jo SJ. Association of metabolic comorbidities with pediatric psoriasis: A systematic review and meta-analysis. Ann Dermatol. 2021;33(3):203–13.

60. deShazo RA, Secrest AM, Armstrong AW, Duffin KC. Addressing hypertension in patients with psoriasis: Review and recommendations. J Psoriasis Psoriatic Arthritis. 2020;5(4):129–38.

61. Susantiningsih T, Mustofa S. Ekspresi IL-6 dan TNF-α pada obesitas. JK Unila. 2018;2(2):174–80.

62. Dewi M. Resistensi insulin terkait obesitas: Mekanisme endokrin dan intrinsik sel. Jurnal Gizi dan Pangan. 2007;2(2):49–54.

63. Yusuf K, Legiran L. Efek sitokin proinflamasi tnf - alpha pada penyakit diabetes melitus tipe 2: Tinjauan literatur. Jurnal Integrasi Kesehatan & Sains. 2024;6(1):22–6.

64. Lukitaningtyas D, Cahyono EA. Hipertensi : Artikel review. Jurnal Pengembangan Ilmu dan Praktik Kesehatan. 2023;2(2):100–17.

65. Ramadhan Fauzan D, Ayu Virginia Irawati N, Yogie Fadli M. Hipertensi dan inflamasi: Sebuah perspektif ke depan untuk target terapi baru. JK Unila. 2020;4(2):135–46.

66. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013;133(2):377–85.

67. Dairov A, Issabekova A, Sekenova A, Shakhatbayev M, Ogay V. Prevalence, incidence, gender and age distribution, and economic burden of psoriasis worldwide and in Kazakhstan. Journal of Clinical Medicine of Kazakhstan. 2024;21(2).

68. Burshtein J, Strunk A, Garg A. Incidence of psoriasis among adults in the United States: A sex- and age-adjusted population analysis. J Am Acad Dermatol. 2021;84(4):1023–9.

69. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. The Lancet. 2021;397(10281):1301–15.

70. Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016;7(6):471–2.

71. Nair PA, Badri T. Psoriasis. In: StatPearls. 2025.

72. Khumairoh MD. Hubungan antara profil (Usia, durasi penyakit, jenis kelamin, tipe klinis, dan riwayat terapi) dengan kualitas hidup pasien psoriasis di RSUD Dr. Saiful Anwar Malang. Tugas Akhir Universitas Brawijaya. 2021;43.

73. Susanti R, Sakundarno Adi M, Setyawan Susanto H, Sutiningsih D, Epidemiologi dan Penyakit Tropik B, Kesehatan Masyarakat F. Gambaran kualitas hidup penderita psoriasis di komunitas psobat Jawa Tengah. Jurnal Kesehatan Masyarakat [Internet]. 2020;8(3):348. Available from: http://ejournal3.undip.ac.id/index.php/jkm

74. Budiastuti A. Korelasi kadar TNF-α dan skor Psoriasis Area and Severity Index (PASI) pada pasien psoriasis. Media Medika Indonesiana. 2011;45(2):133.

75. Budini SS, Cholis M, Rofiq A. Kadar TNF-α lesi kulit dengan derajat keparahan psoriasis vulgaris (TNF-α level in skin lesion with severity scale

of psoriasis vulgaris). Berkala Ilmu Kesehatan Kulit & Kelamin. 2024;26(1):25.

76. Owczarek W. The role of HLA-Cw6 in psoriasis and psoriatic arthritis. Reumatologia/Rheumatology. 2022;60(5):303–5.

77. Schonmann Y, Ashcroft DM, Iskandar IYK, Parisi R, Sde-Or S, Comaneshter D, et al. Incidence and prevalence of psoriasis in Israel between 2011 and 2017. Journal of the European Academy of Dermatology and Venereology. 2019;33(11):2075–81.

78. Sekar Cantika A, Himbawani M. Hubungan derajat keparahan psoriasis vulgaris terhadap kualitas hidup penderita. Jurnal Media Medika Muda. 2022;3.

79. Anggraeni TD. Hubungan ekspresi alel HLA-CW6 dan kadar vitamin D 25-OH. Karya Akhir. 2021;16.

80. Paz-Filho G, Mastronardi C, Franco CB, Wang KB, Wong ML, Licinio J. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arquivos Brasileiros de Endocrinologia & Metabologia. 2015;56(9):597–607.

81. Mamizadeh M, Tardeh Z, Azami M. The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(2):1405–12.

82. Haryono DA, Arifin S, Shinta HE, Widodo T, Yuliani NNS. Hubungan obesitas dan aktivitas fisik dengan kejadian diabetes melitus tipe II pada usia > 40 tahun di wilayah kerja Puskesmas Bukit Hindu. Barigas: Jurnal Riset Mahasiswa. 2024;1(2).

83. Eka Kurniawan A, Risqi Fatmariza A, Fauzi Sabban I, Wahyuni S, Aditya Hermawan R, Laboratorium Medis T, et al. Korelasi kadar tumor nekrosis faktor alpha dan interleukin-6 pada penderita diabetes melitus tipe 2. J Sintesis. 2024;5(2):2024.

84. Yuliasih, Handoyo M, Rahmawati LD, Wibisono S, Nisa N. Correlation Between Insulin Resistance and Psoriatic Arthritis Disease Activity: A Cross-Sectional Study. J Psoriasis Psoriatic Arthritis. 2023;8(4):129–33.

85. Theodorakopoulou E, Yiu ZZN, Bundy C, Chularojanamontri L, Gittins M, Jamieson LA, et al. Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. British Journal of Dermatology. 2019;175(5):1038–44.

86. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2021;55(5):829–35.

87. Fatema F, Ghoshal L, Saha A, Agarwal S, Bandyopadhyay D. Early-Onset Versus Late-Onset Psoriasis: A Comparative Study of Clinical Variables, Comorbidities, and Association with HLA CW6 in a Tertiary Care Center. Indian J Dermatol. 2021;66(6):705.

88. Phan C, Sigal ML, Lhafa M, Barthélémy H, Maccari F, Estève E, et al. Metabolic comorbidities and hypertension in psoriasis patients in France. Comparisons with French national databases. Ann Dermatol Venereol. 2016;143(4):264–74.

89. Lee DC, Young T, Koziatek CA, Shim CJ, Osorio M, Vinson AJ, et al. Age disparities among patients with type 2 diabetes and associated rates of hospital use and diabetic complications. Prev Chronic Dis. 2019;16:180681.

90. Abramczyk R, Queller JN, Rachfal AW, Schwartz SS. Diabetes and psoriasis: Different sides of the same prism. Diabetes, Metabolic Syndrome and Obesity. 2020;13:3571–7.

91. Evanti AM, Kasmitasari F, Irawanto ME. Perbedaan derajat keparahan penyakit berdasarkan skor psoriasis area and severity index (PASI) terhadap profil lipid pada psoriasis vulgaris. Jurnal Health Sains. 2022 Aug 18;3(5):704–16.

92. Rahardjo FN, Adiguna MS, Wardhana M. Derajat keparahan psoriasis vulgaris berkorelasi positif terhadap kadar HBA1C. Medicina (B Aires). 2019 Jan 19;50(1).

93. Ghiasi M, Nouri M, Abbasi A, Hatami P, Abbasi M, Nourijelyani K. Psoriasis and increased prevalence of hypertension and diabetes mellitus. Indian J Dermatol [Internet]. 2011;56(5):533. Available from: https://journals.lww.com/10.4103/0019-5154.87149

94. Najafipour M, Zareizadeh M, Roshanravan N, Najafipour F. The association between severity of psoriasis and diabetes melitus. J Biochem Tech. 2019;1(2):81–4.

95. Takeshita J, Wang S, Shin DB, Mehta NN, Kimmel SE, Margolis DJ, et al. Effect of Psoriasis Severity on Hypertension Control. JAMA Dermatol. 2020;151(2):161.

96. Kim HN, Han K, Song SW, Lee JH. Hypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study. PLoS One. 2018;13(8):e0202854.

97. Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci. 2017;19(1).

98. Lintong PM. Perkembangan konsep patogenesis aterosklerosis. Jurnal Biomedik. 2019;1(1):12–22.

99. Umbas IM, Tuda J, Numansyah M. Hubungan antara merokok dengan hipertensi di puskesmas kawangkoan. e-Journal Keperawatan. 2019;7(1).

100. Sintia Kristiani F, Indria Anggraini D. Psoriasis Pustulosa Generalisata: Tinjauan Kasus Pada Geriatri. Medula. 2020;9(4).

101. Mutmainna, Sofyan A, Nasir M. Psoriasis vulgaris. Jurnal Medical Profession (MedPro). 2020;2(2).

102. Butacu AI, Toma C, Negulet IE, Manole I, Banica AN, Plesea A, et al. Updates on psoriasis in special areas. J Clin Med. 2024 Dec 11;13(24):7549.

103. Tedesco D, Haragsim L. Cyclosporine: A Review. J Transplant. 2012;2012:1–7.

104. Takeshita J, Wang S, Shin DB, Mehta NN, Kimmel SE, Margolis DJ, et al. Effect of Psoriasis Severity on Hypertension Control. JAMA Dermatol. 2020;151(2):161.